Key terms
About FHTX
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FHTX news
Apr 16
7:12am ET
Foghorn Therapeutics Appoints Kristian Humer as New CFO
Apr 16
7:09am ET
Foghorn Therapeutics appoints Humer as Chief Financial Officer
Apr 09
4:52pm ET
Foghorn Therapeutics Unveils Cancer Research Breakthroughs
Mar 08
6:28am ET
Foghorn Therapeutics’ FHD-286: A Promising Contender in AML Treatment and Overcoming TKI Resistance
Mar 07
7:23am ET
Foghorn Therapeutics Unveils New Investor Presentation
Mar 07
7:03am ET
Foghorn Therapeutics expects cash runway into first half of 2026
Mar 07
7:03am ET
Foghorn Therapeutics reports FY23 EPS ($2.34), consensus ($2.48)
Mar 05
5:03pm ET
Foghorn Therapeutics, Eli Lilly to present new preclinical data at AACR
Feb 09
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
Feb 09
4:11am ET
Foghorn’s FHD-909 Advances to Clinical Trials with Eli Lilly
Feb 09
4:11am ET
Foghorn Therapeutics Releases New Investor Presentation
Feb 08
7:11am ET
Foghorn Therapeutics says Lilly selects FHD-909 for clinical development
No recent press releases are available for FHTX
FHTX Financials
Key terms
Ad Feedback
FHTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FHTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
